![Automated C-Path system developed by Stanford researchers takes thousands of measurements not currently used to grade breast cancer tumors.[© Sebastian Kaulitzki - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Nov10_2011_21425225_BreastCancerBlackWhiteIllustration_BreastCancerBresearch1372410755-218x150.jpg "New Therapy Targets Aggressive Chemotherapy-Resistant Breast Cancer")
Immunai said the new funding will allow it to expand its genomics capabilities from the observational to the functional, including reprogramming immune cells as well as prioritizing and validating targets . . .
- Neurological Disorders
- Alzheimers
- Artificial Intelligence
- Autoimmune Disorders
- Cancer
- Virology
- Coronavirus
- Information Management
- Data Analysis
- Data Management
- GEN Edge
- OMICs
- Genomics
- Single Cell Technology
- Single-Cell Genomics
Immunai Expands from Observational to Functional Genomics
Developer of AI-based single-cell immunology database focuses on reprogramming immunity with $60M Series A financing
[L.-R.] Luis Voloch, PhD., Chief Technology Officer of Immunai, and Noam Solomon, PhD, the company’s CEO and Co-founder. Immunai has completed a $60 million Series A financing that it says will enable its expansion into functional genomics, with the goal of improving how it integrates artificial intelligence (AI) and single-cell multi-omics at scale to help its biopharma and healthcare partners better detect, diagnose, and treat disease. [Immunai]
